New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

References

• HowladerNNooneAMKrapchoMSurveillance, Epidemiology, and End Results Program (SEER) Cancer Statistics Review, 1975–2008 Available from: http://seer.cancer.gov/csr/1975_2008/Accessed May 17, 2014
   Google Scholar
• GellerACMillerDRAnnasGDDemierreMFGilchrestBAKohHKMelanoma incidence and mortality among US whites, 1969–1999JAMA20022881719172012365954
   PubMed Web of Science ®Google Scholar
• VeierodMBWeiderpassEThornMA prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in womenJ Natl Cancer Inst2003951530153814559875
   PubMed Web of Science ®Google Scholar
• RhodesARWeinstockMAFitzpatrickTBMihmMCJrSoberAJRisk factors for cutaneous melanoma. A practical method of recognizing predisposed individualsJAMA1987258314631543312689
   PubMed Web of Science ®Google Scholar
• XingYChangGJHuCYConditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysisCancer20101162234224120187100
   PubMed Web of Science ®Google Scholar
• BarthAWanekLAMortonDLPrognostic factors in 1,521 melanoma patients with distant metastasesJ Am Coll Surg19951811932017670677
   PubMed Web of Science ®Google Scholar
• BalchCMSoongSJGershenwaldJEPrognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemJ Clin Oncol2001193622333411504744
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med20113642517252621639810
   PubMed Web of Science ®Google Scholar
• WeberJThompsonJAHamidOA randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaClin Cancer Res2009155591559819671877
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol20101115516420004617
   PubMed Web of Science ®Google Scholar
• O’DaySJMaioMChiarion-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol2010211712171720147741
   PubMed Web of Science ®Google Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol2014321020103024590637
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med20113642507251621639808
   PubMed Web of Science ®Google Scholar
• McArthurGAChapmanPBRobertCSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyLancet Oncol20141532333224508103
   PubMed Web of Science ®Google Scholar
• SeetharamuNTuTJChristosPEnrollment in clinical trials correlates with improved survival in metastatic melanomaOncology20128140340922270052
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med20123671694170323020132
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature200241794995412068308
   PubMed Web of Science ®Google Scholar
• CurtinJAFridlyandJKageshitaTDistinct sets of genetic alterations in melanomaN Engl J Med20053532135214716291983
   PubMed Web of Science ®Google Scholar
• PaikPKArcilaMEFaraMClinical characteristics of patients with lung adenocarcinomas harboring BRAF mutationsJ Clin Oncol2011292046205121483012
   PubMed Web of Science ®Google Scholar
• SantarpiaLQiYStemke-HaleKMutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersBreast Cancer Res Treat201213433334322538770
   PubMed Web of Science ®Google Scholar
• SingerGOldtR3rdCohenYMutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinomaJ Natl Cancer Inst20039548448612644542
   PubMed Web of Science ®Google Scholar
• SingerGKurmanRJChangHWChoSKShihIeMDiverse tumorigenic pathways in ovarian serous carcinomaAm J Pathol20021601223122811943707
   PubMed Web of Science ®Google Scholar
• SiebenNLMacropoulosPRoemenGMIn ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumoursJ Pathol200420233634014991899
   PubMed Web of Science ®Google Scholar
• KimuraETNikiforovaMNZhuZKnaufJANikiforovYEFaginJAHigh prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinomaCancer Res2003631454145712670889
   PubMed Web of Science ®Google Scholar
• LupiCGianniniRUgoliniCAssociation of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinomaJ Clin Endocrinol Metab2007924085409017785355
   PubMed Web of Science ®Google Scholar
• CaroniaLMPhayJEShahMHRole of BRAF in thyroid oncogenesisClin Cancer Res2011177511751721900390
   PubMed Web of Science ®Google Scholar
• HutchinsGSouthwardKHandleyKValue of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancerJ Clin Oncol2011291261127021383284
   PubMed Web of Science ®Google Scholar
• ShinozakiMFujimotoAMortonDLHoonDSIncidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomasClin Cancer Res2004101753175715014028
   PubMed Web of Science ®Google Scholar
• MaldonadoJLFridlyandJPatelHDeterminants of BRAF mutations in primary melanomasJ Natl Cancer Inst2003951878189014679157
   PubMed Web of Science ®Google Scholar
• LongGVMenziesAMNagrialAMPrognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanomaJ Clin Oncol2011291239124621343559
   PubMed Web of Science ®Google Scholar
• LukeJJHodiFSVemurafenib and BRAF inhibition: a new class of treatment for metastatic melanomaClin Cancer Res20121891422083257
   PubMed Web of Science ®Google Scholar
• LukeJJHodiFSIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaOncologist20131871712523709751
   PubMed Web of Science ®Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature201046897397721107323
   PubMed Web of Science ®Google Scholar
• JohannessenCMBoehmJSKimSYCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature201046896897221107320
   PubMed Web of Science ®Google Scholar
• WagleNEmeryCBergerMFDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profilingJ Clin Oncol2011293085309621383288
   PubMed Web of Science ®Google Scholar
• PoulikakosPIPersaudYJanakiramanMRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature201148038739022113612
   PubMed Web of Science ®Google Scholar
• ShiHMoriceauGKongXMelanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistanceNat Commun2012372422395615
   PubMed Web of Science ®Google Scholar
• StraussmanRMorikawaTSheeKTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature201248750050422763439
   PubMed Web of Science ®Google Scholar
• ShiHHongAKongXA novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionCancer Discov20144697924265152
   PubMed Web of Science ®Google Scholar
• ShiHHugoWKongXAcquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyCancer Discov20144809324265155
   PubMed Web of Science ®Google Scholar
• Van AllenEMWagleNSuckerAThe genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaCancer Discov201449410924265153
   PubMed Web of Science ®Google Scholar
• KimKBFlahertyKTChapmanPBPattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM)J Clin Oncol201129 Suppl8519
   Web of Science ®Google Scholar
• AckermanAKleinOMcDermottDFOutcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsCancer2272014 [Epub ahead of print.]
   Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci U S A20111087535734021502504
   PubMed Web of Science ®Google Scholar
• ChaftJEOxnardGRSimaCSKrisMGMillerVARielyGJDisease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial designClin Cancer Res2011176298630321856766
   PubMed Web of Science ®Google Scholar
• Le CesneARay-CoquardIBuiBNDiscontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialLancet Oncol20101194294920864406
   PubMed Web of Science ®Google Scholar
• JosephEWPratilasCAPoulikakosPIThe RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerProc Natl Acad Sci U S A2010107149031490820668238
   PubMed Web of Science ®Google Scholar
• PoulikakosPIZhangCBollagGShokatKMRosenNRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature201046442743020179705
   PubMed Web of Science ®Google Scholar
• HatzivassiliouGSongKYenIRAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature201046443143520130576
   PubMed Web of Science ®Google Scholar
• HeidornSJMilagreCWhittakerSKinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFCell201014020922120141835
   PubMed Web of Science ®Google Scholar
• OberholzerPAKeeDDziunyczPRAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitorsJ Clin Oncol20123031632122067401
   PubMed Web of Science ®Google Scholar
• GregerJEastmanSZhangVCombinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsMol Cancer Ther20121190992022389471
   PubMed Web of Science ®Google Scholar
• SuFVirosAMilagreCRAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsN Engl J Med201236620721522256804
   PubMed Web of Science ®Google Scholar
• InfanteJRFalchookGSLawrenceDPPhase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)J Clin Oncol201129SupplCRA8503
   Google Scholar
• WagleNVan AllenEMTreacyDJMAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionCancer Discov20144616824265154
   PubMed Web of Science ®Google Scholar
• Tafinlar [full prescribing information] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdfAccessed May 17, 2014
   Google Scholar
• Mekinist [full prescribing information] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl.pdfAccessed May 17, 2014
   Google Scholar
• InfanteJRFecherLAFalchookGSSafety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialLancet Oncol20121377378122805291
   PubMed Web of Science ®Google Scholar
• YamaguchiTKakefudaRTajimaNSowaYSakaiTAntitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivoInt J Oncol201139233121523318
   PubMed Web of Science ®Google Scholar
• FalchookGSLongGVKurzrockRDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialLancet20123791893190122608338
   PubMed Web of Science ®Google Scholar
• LongGVTrefzerUDaviesMADabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialLancet Oncol2012131087109523051966
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet201238035836522735384
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJDemidovLAn update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)J Clin Oncol2013Suppl 319013
   Google Scholar
• FalchookGSLewisKDInfanteJRActivity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialLancet Oncol20121378278922805292
   PubMed Web of Science ®Google Scholar
• KimKBKeffordRPavlickACPhase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorJ Clin Oncol20133148248923248257
   PubMed Web of Science ®Google Scholar
• FlahertyKTRobertCHerseyPImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med201236710711422663011
   PubMed Web of Science ®Google Scholar
• GoldingerSMZimmerLSchulzCUpstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsEur J Cancer20145040641024183461
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineGSK announces headline results for Phase III study of the combination of Tafinlar^® (dabrafenib) and Mekinist^®(trametinib) in metastatic melanoma Available from: http://us.gsk.com/html/media-news/pressreleases/2014/gsk-announces-headline-results-for-phase-iii-study-of-the-combin.htmlAccessed May 17, 2014
   Google Scholar
• BealeSDicksonRBagustAVemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisalPharmacoeconomics2013311121112924114739
   PubMed Web of Science ®Google Scholar
• DaudAAshworthMKeffordRFPyrexia in patients treated with dabrafenib and trametinib for BRAFV600 mutation-positive metastatic melanomaPigment Cell Melanoma Res201326945
   Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med201336913414423724846
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med20123662443245422658127
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med201336912213323724867
   PubMed Web of Science ®Google Scholar
• OttPAHodiFSRobertCCTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patientsClin Cancer Res2013195300530924089443
   PubMed Web of Science ®Google Scholar
• BoniACogdillAPDangPSelective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte functionCancer Res2010705213521920551059
   PubMed Web of Science ®Google Scholar
• RibasAHodiFSCallahanMKontoCWolchokJHepatotoxicity with combination of vemurafenib and ipilimumabN Engl J Med20133681365134623550685
   PubMed Web of Science ®Google Scholar
• OttPAHenryTBarandaSJInhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC propertiesCancer Immunol Immunother20136281182223306863
   PubMed Web of Science ®Google Scholar
• LukeJJOttPAKinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?Expert Opin Pharmacother2013142457246224138302
   PubMed Web of Science ®Google Scholar